Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001731122-25-000837
Filing Date
2025-06-09
Accepted
2025-06-09 17:30:47
Documents
1
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 7451
  Complete submission text file 0001731122-25-000837.txt   8925
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Issuer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address FALLMERAYER STR. 19 MUNICH 2M 80796
Business Address
Thomas Steffen (Reporting) CIK: 0001646396 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37606 | Film No.: 251035195